We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Read MoreHide Full Article
Key Takeaways
Eli Lilly signed a deal worth up to $2.75B with Insilico for AI-driven drug discovery rights.
LLY is integrating AI across R&D, using platforms to speed drug discovery and cut timelines.
Healthcare ETFs like IHE offer diversified exposure to AI-focused pharma leaders.
U.S. pharma giant Eli Lilly (LLY - Free Report) has just thrust the rapidly evolving field of artificial intelligence (AI)-driven drug discovery into the spotlight, signing a landmark deal worth up to $2.75 billion with Hong Kong-based Insilico Medicine. The agreement, announced on March 29, 2026, grants LLY global rights to develop and commercialize drugs discovered using Insilico’s generative AI platform.
Against a backdrop of rapid AI integration — from diagnostic imaging to personalized medicine — this collaboration reinforces a broader industry trend.
For investors, this move squarely puts the spotlight on healthcare exchange-traded funds (ETFs), particularly those with heavy exposure to pharmaceutical giants like Lilly that are aggressively pursuing this new frontier as a strategic way to capture the upside of the AI-pharma revolution.
Before analyzing the ETFs that offer the best exposure in this case, it is important to understand how deeply AI is being integrated into drug development. The FDA has already noted a significant increase in drug applications incorporating AI components, while the scientific community continues to mark key clinical milestones.
The AI-Powered Drug Market: Eli Lily & Others
With AI being practically woven into the very fabric of the healthcare sector at present, the global AI drug discovery market is projected to skyrocket, with estimates suggesting it could reach $10.3 billion by 2031 (as per Morder Intelligence).
One of the pioneers in the AI-developed drug space is undoubtedly Eli Lily, with the company aggressively integrating AI across its entire R&D pipeline, aiming to transform drug discovery from a slow, linear process into a rapid, iterative, data-driven cycle, to reduce development times and create novel therapeutic candidates. The company recently launched Lilly TuneLab, an AI platform that provides biotech partners with access to proprietary drug discovery models trained on over $1 billion in research data.
Its latest collaboration with Insilico, which has developed 28 AI-driven drugs—nearly half of which are in clinical stages—should help LLY leverage Insilico’s Pharma.AI platform. This enables the company to bypass the slow, trial-and-error nature of traditional chemistry and use generative models to design best-in-class oral therapeutics with greater speed.
Considering the rapidly expanding global AI drug discovery market, other industry titans are following suit. For instance, Pfizer (PFE - Free Report) is leveraging AI to shorten clinical trial timelines, while Novartis (NVS - Free Report) and AstraZeneca have entered into multibillion-dollar deals to integrate AI into their oncology and immunology pipelines. Merck (MRK - Free Report) is using AI to screen vast chemical libraries, simulate molecular interactions, and optimize small-molecule development.
The Case for Healthcare ETFs
Despite the immense potential of the AI-developed drug market, selecting a single winner carries significant idiosyncratic risk.
For instance, a promising AI-designed drug could face a sudden FDA rejection or clinical trial failure, leading to a massive stock slump.
Therefore, by utilizing a "basket approach" through healthcare ETFs, investors can gain exposure to the collective success of the AI pioneers while buffering against the volatility of individual stock picks.
Healthcare ETFs in Spotlight
For investors looking to capitalize on the trend of the healthcare sector’s rapid shift toward AI, the following ETFs offer a great strategic advantage:
This fund, with net assets worth $963.3 million, offers exposure to 56 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines. Its top three holdings include: Johnson & Johnson (23.42%), LLY (20.79%), and MRK (4.87%). PFE holds the fifth position in this fund, with 4.69% weightage.
IHE has surged 21.1% over the past year. The fund charges 38 basis points (bps) in fees.
This fund, with net assets worth $1.26 billion, offers exposure to 26 companies involved in pharmaceuticals, including pharmaceutical research and development as well as production, marketing and sales of pharmaceuticals. Its top three holdings include: LLY (18.64%), NVS (10.78%) and MRK (9.78%). PFE holds the fourth position in this fund, with 5.25% weightage.
PPH has soared 13% over the past year. The fund charges 36 bps in fees.
Vanguard Health Care Index Fund ETF Shares (VHT - Free Report)
With net assets of $17.7 billion, this fund offers exposure to 410 companies across health care equipment and supplies, health care services, and the research, development, production, and marketing of pharmaceutical and biotechnology products. Its top three holdings include: LLY (12.54%), Johnson & Johnson (8.76%) and AbbVie (6.09%). MRK holds the fourth position in this fund, with 4.56% weightage.
VHT has gained 2% over the past year. The fund charges 9 bps in fees.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Key Takeaways
U.S. pharma giant Eli Lilly (LLY - Free Report) has just thrust the rapidly evolving field of artificial intelligence (AI)-driven drug discovery into the spotlight, signing a landmark deal worth up to $2.75 billion with Hong Kong-based Insilico Medicine. The agreement, announced on March 29, 2026, grants LLY global rights to develop and commercialize drugs discovered using Insilico’s generative AI platform.
Against a backdrop of rapid AI integration — from diagnostic imaging to personalized medicine — this collaboration reinforces a broader industry trend.
For investors, this move squarely puts the spotlight on healthcare exchange-traded funds (ETFs), particularly those with heavy exposure to pharmaceutical giants like Lilly that are aggressively pursuing this new frontier as a strategic way to capture the upside of the AI-pharma revolution.
Before analyzing the ETFs that offer the best exposure in this case, it is important to understand how deeply AI is being integrated into drug development. The FDA has already noted a significant increase in drug applications incorporating AI components, while the scientific community continues to mark key clinical milestones.
The AI-Powered Drug Market: Eli Lily & Others
With AI being practically woven into the very fabric of the healthcare sector at present, the global AI drug discovery market is projected to skyrocket, with estimates suggesting it could reach $10.3 billion by 2031 (as per Morder Intelligence).
One of the pioneers in the AI-developed drug space is undoubtedly Eli Lily, with the company aggressively integrating AI across its entire R&D pipeline, aiming to transform drug discovery from a slow, linear process into a rapid, iterative, data-driven cycle, to reduce development times and create novel therapeutic candidates. The company recently launched Lilly TuneLab, an AI platform that provides biotech partners with access to proprietary drug discovery models trained on over $1 billion in research data.
Its latest collaboration with Insilico, which has developed 28 AI-driven drugs—nearly half of which are in clinical stages—should help LLY leverage Insilico’s Pharma.AI platform. This enables the company to bypass the slow, trial-and-error nature of traditional chemistry and use generative models to design best-in-class oral therapeutics with greater speed.
Considering the rapidly expanding global AI drug discovery market, other industry titans are following suit. For instance, Pfizer (PFE - Free Report) is leveraging AI to shorten clinical trial timelines, while Novartis (NVS - Free Report) and AstraZeneca have entered into multibillion-dollar deals to integrate AI into their oncology and immunology pipelines. Merck (MRK - Free Report) is using AI to screen vast chemical libraries, simulate molecular interactions, and optimize small-molecule development.
The Case for Healthcare ETFs
Despite the immense potential of the AI-developed drug market, selecting a single winner carries significant idiosyncratic risk.
For instance, a promising AI-designed drug could face a sudden FDA rejection or clinical trial failure, leading to a massive stock slump.
Therefore, by utilizing a "basket approach" through healthcare ETFs, investors can gain exposure to the collective success of the AI pioneers while buffering against the volatility of individual stock picks.
Healthcare ETFs in Spotlight
For investors looking to capitalize on the trend of the healthcare sector’s rapid shift toward AI, the following ETFs offer a great strategic advantage:
iShares U.S. Pharmaceuticals ETF (IHE - Free Report)
This fund, with net assets worth $963.3 million, offers exposure to 56 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines. Its top three holdings include: Johnson & Johnson (23.42%), LLY (20.79%), and MRK (4.87%). PFE holds the fifth position in this fund, with 4.69% weightage.
IHE has surged 21.1% over the past year. The fund charges 38 basis points (bps) in fees.
VanEck Pharmaceutical ETF (PPH - Free Report)
This fund, with net assets worth $1.26 billion, offers exposure to 26 companies involved in pharmaceuticals, including pharmaceutical research and development as well as production, marketing and sales of pharmaceuticals. Its top three holdings include: LLY (18.64%), NVS (10.78%) and MRK (9.78%). PFE holds the fourth position in this fund, with 5.25% weightage.
PPH has soared 13% over the past year. The fund charges 36 bps in fees.
Vanguard Health Care Index Fund ETF Shares (VHT - Free Report)
With net assets of $17.7 billion, this fund offers exposure to 410 companies across health care equipment and supplies, health care services, and the research, development, production, and marketing of pharmaceutical and biotechnology products. Its top three holdings include: LLY (12.54%), Johnson & Johnson (8.76%) and AbbVie (6.09%). MRK holds the fourth position in this fund, with 4.56% weightage.
VHT has gained 2% over the past year. The fund charges 9 bps in fees.